Patterns and Predictors of Mortality After Waitlist Dropout of Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation

被引:6
|
作者
Gorgen, Andre [1 ,2 ]
Rosales, Roizar [1 ]
Sadler, Erin [2 ]
Beecroft, Robert [3 ]
Knox, Jennifer [4 ]
Dawson, Laura A. [5 ]
Ghanekar, Anand [1 ,2 ]
Grant, David [1 ,2 ]
Greig, Paul D. [1 ,2 ]
Sapisochin, Gonzalo [1 ,2 ]
机构
[1] Univ Toronto, Univ Hlth Network, Multiorgan Transplant Program, Toronto, ON, Canada
[2] Univ Toronto, Dept Gen Surg, Toronto, ON, Canada
[3] Univ Toronto, Univ Hlth Network, Div Intervent Radiol, Joint Dept Imaging, Toronto, ON, Canada
[4] Univ Toronto, Princess Margaret Canc Ctr, Dept Med Oncol, Toronto, ON, Canada
[5] Univ Toronto, Princess Margaret Canc Ctr, Dept Radiat Oncol, Radiat Med Program, Toronto, ON, Canada
关键词
SURVIVAL; MODEL; RISK; CANDIDATES; DIAGNOSIS; RATES;
D O I
10.1097/TP.0000000000002616
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. There is a lack of information about survival after dropout from the liver transplant waiting list. Therefore, we aimed to assess the overall survival, and risk factors for death, after waiting list dropout due to hepatocellular carcinoma (HCC) progression. Methods. We assessed patients who dropped out of the liver transplant waiting list between 2000 and 2016 in a single, large academic North American center. Patients were divided into 3 groups according to the types of HCC progression: locally advanced disease (LAD), extrahepatic disease (EHD), and macrovascular invasion (MVI). The primary outcome was overall survival. Survival was assessed by the Kaplan-Meier method. Predictors of death after dropout were assessed by multivariable Cox regression. Results. During the study period, 172 patients dropped out due to HCC progression. Of those, 37 (21.5%), 74 (43%), and 61 (35.5%) dropped out due to LAD, EHD, and MVI, respectively. Median survival according to cause of dropout (LAD, EHD, or MVI) was 1.0, 4.4, or 3.3 months, respectively (P = 0.01). Model for End-stage Liver Disease (MELD) score (hazard ratio [HR], 1.04; 95% confidence interval [CI], 1.01-1.08), alcoholic liver disease (HR, 1.66; 95% CI, 1.02-2.71), and alpha-fetoprotein >1000 ng/mL (HR, 1.86; 95% CI, 1.22-2.84) were predictors of mortality after dropout. Dropout due to EHD (HR, 0.61; 95% CI, 0.38-0.98) and undergoing treatment after dropout were protective factors (HR, 0.32; 95% CI, 0.21-0.48) for death. Conclusions. Patient prognosis after dropout is dismal. However, a subgroup of patients may have longer survival. The present study identifies the patterns of waitlist dropout in patients with HCC and provides evidence for the effectiveness of treatment strategies offered to HCC patients after dropout.
引用
收藏
页码:2136 / 2143
页数:8
相关论文
共 50 条
  • [1] MACHINE LEARNING TO PREDICT WAITLIST DROPOUT IN PATIENTS WITH HEPATOCELLULAR CARCINOMA AWAITING LIVER TRANSPLANTATION
    Mehta, Neil
    Arshad, Sahar
    Ho, Ryan
    Suleman, Tashfeen
    Kwong, Allison J.
    Ho, Isaac
    Yao, Francis
    Hameed, Bilal
    HEPATOLOGY, 2019, 70 : 123A - 123A
  • [2] Risk factors for liver transplant waitlist dropout in patients with hepatocellular carcinoma
    Park, Sang-Jae
    Freise, Chris E.
    Hirose, Ryutaro
    Kerlan, Robert K.
    Yao, Francis Y.
    Roberts, John P.
    Vagefi, Parsia A.
    CLINICAL TRANSPLANTATION, 2012, 26 (04) : E359 - E364
  • [3] Locoregional Therapy for Hepatocellular Carcinoma Decreases Liver Transplant Waitlist Dropout and Mortality.
    Weeks, S.
    Ishaque, T.
    Massie, A.
    Segev, D.
    King, E.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 : 819 - 819
  • [4] Role of Locoregional Therapy and Predictors for Dropout in Patients with Hepatocellular Carcinoma Listed for Liver Transplantation
    Sheth, Rahul A.
    Patel, Madhukar S.
    Koottappillil, Brian
    Shah, Jigesh A.
    Oklu, Rahmi
    Mueller, Peter
    Vagefi, Parsia A.
    Ganguli, Suvranu
    JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2015, 26 (12) : 1761 - 1768
  • [5] Outcomes and Predictors of Mortality After Dropout of Patients with HCC Listed for Liver Transplantation
    Gorgen, Andre
    Rosales, Roizar
    Beecroft, Robert
    Knox, Jennifer
    Dawson, Laura
    Ghanekar, Anand
    Grant, David
    Greig, Paul
    Sapisochin, Gonzalo
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 81 - 81
  • [6] Cirrhosis-Driven Immune Dysfunction is Associated with Poor Response to DEB-TACE and Waitlist Dropout in Hepatocellular Carcinoma Patients While Awaiting Liver Transplantation
    Nunez, K.
    Sandow, T.
    Hibino, M.
    Cohen, A.
    Thevenot, P.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 492 - 492
  • [7] Predictors of survival in patients with hepatocellular carcinoma after liver transplantation
    Gedaly, Roberto
    Gilbert, Jeffrey
    Johnston, Thomas D.
    Jeon, Hoonbae
    Shokouh-Amiri, Hosein
    Vera, Santiago
    Koch, Alvaro
    Ranjan, Dinesh
    TRANSPLANT INTERNATIONAL, 2007, 20 : 258 - 258
  • [8] Predictors of Time To Recurrence and Mortality in Patients Developing Recurrent Hepatocellular Carcinoma After Liver Transplantation
    Bodzin, Adam
    Reino, Diego
    Lunsford, Keri
    Harlander-Locke, Michael
    Markovic, Daniela
    Zarrinpar, Ali
    Kaldas, Fady
    Farmer, Douglas
    Yersiz, Hassan
    Busuttil, Ronald
    Agopian, Vatche
    AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15 : 89 - 89
  • [9] The essential predictors of recurrence in patients with hepatocellular carcinoma after liver transplantation
    Ozer, Ali
    ANNALS OF CLINICAL AND ANALYTICAL MEDICINE, 2020, 11 (01): : 64 - 66
  • [10] Incidence Rate and Predictors of de novo Overt Hepatocellular Carcinoma in Cirrhotic Patients Awaiting Liver Transplantation
    Machicado, Jorge D.
    Batra, Sachin
    Dasher, Kevin
    Pan, Jen-Jung
    Bynon, Steve
    Fallon, Michael B.
    Machicao, Victor I.
    GASTROENTEROLOGY, 2014, 146 (05) : S942 - S942